Taylor Boyd

Abzena has appointed Taylor Boyd as Chief Business Officer

Abzena has announced the appointment of Taylor Boyd to the newly created role of Chief Business Officer.

Boyd joins the company from Longboard Pharmaceuticals, where he most recently served as Head of Business Development.

Prior to this, he was Vice President of Investor Relations at Oxford Biomedica and, earlier in his career, was an investment banker covering the biopharmaceutical sector for Raymond James, Leerink Partners, Cantor Fitzgerald and RBC Capital Markets.

In his new role, Boyd will be responsible for Abzena’s corporate development, portfolio strategy and partnering strategy activities.

Commenting on his latest venture, Boyd said: “I look forward to leveraging my experience to enhance our corporate development efforts and build strategic partnerships that deliver impactful solutions that meet the evolving needs of our customers.”

Abzena’s Chief Executive Officer, Matt Stober, added: “We are thrilled to welcome Taylor to Abzena’s executive leadership team… Taylor’s extensive expertise in corporate strategy and due diligence will be invaluable as we look to achieve [our] strategic vision and deliver… solutions that move medicines forward to patients faster.”